News

Munich, Germany and Menlo Park, Calif. – March 26, 2019 — Breath Therapeutics, a private company developing advanced inhaled therapeutics in severe pulmonary orphan diseases, announced today the initiation of the Phase 3 BOSTON clinical studies of L-CsA-i for the treatment of Bronchiolitis Obliterans Syndrome (BOS).

Munich, Germany and Menlo Park, Calif. –  March 20, 2019 — Breath Therapeutics, a private company developing advanced inhaled therapeutics in severe pulmonary orphan diseases, today announced presentations at three upcoming scientific conferences.

Munich, Frankfurt, Boston, October 17, 2018 — Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Peter Shadday as Chief Commercial Officer. He joins the executive management team and will lead Breath’s activities related to market access and product commercialization.

Munich, Frankfurt, Boston, July 11, 2018 — Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Noreen Roth Henig, M.D. as Chief Medical Officer. Dr. Henig joins the executive management team and will lead Breath’s clinical development activities.

Munich, Frankfurt, Boston, November 28, 2017 — Breath Therapeutics B.V. (Breath), a company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Renu Gupta, M.D. to its Board of Directors. Dr. Gupta will join the Board of Directors as an executive member.

Breath Therapeutics BV, a PARI Pharma GmbH spin-out developing advanced drug-aerosol therapeutics in pulmonary orphan indications, today announced the closing of a USD 46 million Series A financing round.

Sign-up for News and Updates from Breath

  • This field is for validation purposes and should be left unchanged.